Skip to main content
. Author manuscript; available in PMC: 2014 Nov 20.
Published in final edited form as: Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597

Fig. 6. iCARs restrict 19-28z CAR target cell specificity in vivo.

Fig. 6

(A) BLI depicting the tumor progress of NALM/6 or NALM/6-PSMA in NOD/SCID/γc− mice treated with sorted 19-28z/PD-1 iCAR-P T cells. Untreated mice (no T cells) were used as control. (B) Tumor burden for each mouse was quantified, and average total flux per group is shown. (C) Spleen weight of mice from (A) sacrificed at day 21. Each dot represents one recipient mouse. (D) Flow cytometric analysis of the femur bone marrow from (C) for the presence of tumor cells (CD19+GFP+) and T cells (CD19−19-28z/GFP+CD4+CD8+). 19-28z expression was assessed by staining for LNGFR receptor whose complementary DNA (cDNA) is linked to 19-28z and is used as a detection marker. (E and F) Absolute numbers of tumor cells (E) and of CD19−19-28z/GFP+CD4+CD8+ T cells (F) in the spleens from (C) were quantified by flow cytometry with CountBright beads (n = 4). Error bars represent ±SEM. **P < 0.01, ***P < 0.001 by Student’s t test.